<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Ferrous gluconate: Pediatric drug information</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Ferrous gluconate: Pediatric drug information</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="drugTitle">Ferrous gluconate: Pediatric drug information</div><div class="clear"></div><div id="topicText">(For additional information <a class="drug drug_general" data-topicid="8443" href="/d/html/8443.html" rel="external">see "Ferrous gluconate: Drug information"</a> and <a class="drug drug_patient" data-topicid="11192" href="/d/html/11192.html" rel="external">see "Ferrous gluconate: Patient drug information"</a>)<br/><br/>For abbreviations, symbols, and age group definitions used in Lexicomp (<a class="graphic graphic_table" href="/d/html/57469.html" rel="external">show table</a>)<div class="visuallyHidden drugH1Div" id="formulinkBodyPlaceholder"><span class="drugH1"></span></div>
<div class="list ubnlist drugH1Div drugBrandNames" id="F170833"><span class="drugH1">Brand Names: US</span>
<ul>
<li>Ferate [OTC]</li></ul></div>
<div class="list_set htclist drugH1Div drugBrandNames" id="F1013969"><span class="drugH1">Therapeutic Category</span>
<ul>
<li>
<span class="list-set-name">Iron Salt</span>;</li>
<li>
<span class="list-set-name">Mineral, Oral</span></li></ul></div>
<div class="block dop drugH1Div" id="F170853"><span class="drugH1">Dosing: Pediatric</span>
<p style="text-indent:0em;display:inline">
<b>Note:</b> Doses expressed as <b>elemental</b> iron. Ferrous gluconate contains ~12% elemental iron.</p>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="3b0ee2a9-312e-40f6-bf33-ca2ac2186e1f">Iron deficiency, prevention</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Iron deficiency, prevention:</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<i>WHO recommendations:</i></p>
<p style="text-indent:-2em;margin-left:6em;">Areas where anemia prevalence is ≥40%:</p>
<p style="text-indent:-2em;margin-left:8em;">Infants ≥6 months and Children &lt;2 years: Oral: 10 to 12.5 mg <b>elemental</b> iron daily for 3 consecutive months in a year (WHO 2016b).</p>
<p style="text-indent:-2em;margin-left:8em;">Children 2 to &lt;5 years: Oral: 30 mg <b>elemental</b> iron daily for 3 consecutive months in a year (WHO 2016b).</p>
<p style="text-indent:-2em;margin-left:8em;">Children ≥5 to 12 years: Oral: 30 to 60 mg <b>elemental</b> iron daily for 3 consecutive months in a year (WHO 2016b).</p>
<p style="text-indent:-2em;margin-left:8em;">Adolescent menstruating patients (nonpregnant patients of reproductive potential): Oral: 30 to 60 mg <b>elemental</b> iron daily for 3 consecutive months in a year (WHO 2016a).</p>
<p style="text-indent:-2em;margin-left:6em;">Areas where anemia prevalence 20% to &lt;40%: Weekly intermittent dosing:</p>
<p style="text-indent:-2em;margin-left:8em;">Children 2 to &lt;5 years: Oral: 25 mg <b>elemental</b> iron once <b>weekly</b> for 3 consecutive months, then alternating 3 months off supplementation, 3 months on supplementation (WHO 2011).</p>
<p style="text-indent:-2em;margin-left:8em;">Children 5 to 12 years: Oral: 45 mg <b>elemental</b> iron once <b>weekly</b> for 3 consecutive months, then alternating 3 months off supplementation, 3 months on supplementation (WHO 2011).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="20a2461c-e047-45f3-8199-e7b1c5af6f70">Iron deficiency, treatment</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Iron deficiency, treatment:</b> Oral: Children and Adolescents: Oral: Initial: 3 mg <b>elemental</b> iron/kg/day as a single daily dose (Kazal 2002; Oski 1993; Powers 2017; Reeves 1985) up to 60 to 120 mg <b>elemental</b> iron once daily (AAP [Kleinman 2019]); higher doses may be needed in select patients; dosage range: 3 to 6 mg/kg/day in 1 to 3 divided doses; usual maximum daily dose: 150 to 200 mg <b>elemental </b>iron/<b>day</b> (ASPEN [Corkins 2015]; Kliegman 2020; Zlotkin 2001); once-daily administration may be preferred for ease of administration and adherence (Zlotkin 2001). Studies in iron-depleted adults suggest that iron absorption may be improved by less frequent dosing (alternate-day dosing, or once daily versus multiple daily doses) (Moretti 2015; Stoffel 2017).</p></div>
</div>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosage adjustment for concomitant therapy:</b> Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.</p></div>
<div class="block doa drugH1Div" id="F170837"><span class="drugH1">Dosing: Adult</span><p>(For additional information <a class="drug drug_general" data-topicid="8443" href="/d/html/8443.html" rel="external">see "Ferrous gluconate: Drug information"</a>)</p>
<p style="text-indent:0em;display:inline">
<b>Note:</b>
<b>Dosage expression: </b>Dose is expressed in terms of elemental iron; ferrous gluconate contains ~12% elemental iron per mg of mineral salt (eg, each 324 mg tablet contains ~38 mg elemental iron). <b>Formulation:</b> Enteric-coated and slow/sustained-release preparations are generally not preferred due to poor absorption (Hershko 2014; Liu 2012). <b>Route of administration:</b> IV iron replacement is preferred over oral replacement in several clinical situations (eg, poor GI absorption, lack of response to or poor tolerability of oral iron, chronic kidney disease, active inflammatory bowel disease, cancer, chronic or extensive blood loss) (Auerbach 2021).</p>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="a53f6d47-419d-442f-b670-a934e4739018">Iron deficiency or iron-deficiency anemia</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Iron deficiency or iron-deficiency anemia: Oral:</b> 27 to 38 mg of elemental iron (1 tablet) once every other day or on Monday, Wednesday, and Friday. <b>Note:</b> Daily dosing has been shown to result in decreased absorption but may be reasonable in some individuals to improve adherence (Auerbach 2021; Stoffel 2017; Stoffel 2020).</p></div>
</div>
<p style="text-indent:-2em;margin-left:2em;margin-top:0em;">
<b>Dosage adjustment for concomitant therapy:</b> Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.</p></div>
<div class="block adr drugH1Div" id="F170811"><span class="drugH1">Adverse Reactions</span>
<p style="text-indent:0em;display:inline">The following adverse drug reactions and incidences are derived from product labeling unless otherwise specified. Frequency not defined.</p>
<p style="text-indent:-2em;margin-left:2em;">&gt;10%: Gastrointestinal: Constipation, darkening of stools, nausea, stomach cramps, vomiting</p>
<p style="text-indent:-2em;margin-left:2em;">1% to 10%:</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Dental discoloration, diarrhea, heartburn</p>
<p style="text-indent:-2em;margin-left:4em;">Genitourinary: Urine discoloration</p>
<p style="text-indent:-2em;margin-left:2em;">&lt;1%, postmarketing, and/or case reports: Contact dermatitis</p></div>
<div class="block coi drugH1Div" id="F170825"><span class="drugH1">Contraindications</span>
<p style="text-indent:0em;display:inline">Hemochromatosis, hemolytic anemia.</p></div>
<div class="block war drugH1Div" id="F170808"><span class="drugH1">Warnings/Precautions</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Disease-related concerns:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Gastrointestinal disease: Avoid in patients with peptic ulcer, enteritis, or ulcerative colitis.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Special populations:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Blood transfusion recipients: Avoid in patients receiving frequent blood transfusions.</p>
<p style="text-indent:-2em;margin-left:4em;">• Older adult: Anemia in the elderly is often caused by “anemia of chronic disease” or associated with inflammation rather than blood loss. Iron stores are usually normal or increased, with a serum ferritin &gt;50 ng/mL and a decreased total iron binding capacity. Hence, the “anemia of chronic disease” is not secondary to iron deficiency but the inability of the reticuloendothelial system to reclaim available iron stores.</p>
<p style="text-indent:-2em;margin-left:4em;">• Pediatric: Accidental overdose of iron-containing products is a leading cause of fatal poisoning in children under 6 years of age. Keep this product out of the reach of children. In case of accidental overdose call the poison control center immediately.</p>
<p style="text-indent:-2em;margin-left:4em;">• Premature infants: Avoid use in premature infants until the vitamin E stores, deficient at birth, are replenished.</p>
<p style="text-indent:-2em;margin-left:2em;">
<i>
<b>Dosage form specific issues: </b></i></p>
<p style="text-indent:-2em;margin-left:4em;">• Oral iron formulations: Immediate release oral iron products are preferred for treatment of iron deficiency anemia; enteric coated and slow/sustained release preparations are not desired due to poor absorption (Hershko 2014; Liu 2012).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Other warnings/precautions:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Duration of therapy: Administration of iron for &gt;6 months should be avoided except in patients with continuous bleeding or menorrhagia.</p></div>
<div class="block add-pediatric-warn-info drugH1Div" id="F52878455"><span class="drugH1">Warnings: Additional Pediatric Considerations</span>
<p style="text-indent:0em;display:inline">Consider all iron sources when evaluating the dose of iron, including combination products, infant formulas, and liquid nutritional supplements.</p></div>
<div class="block dosfc drugH1Div" id="F46576380"><span class="drugH1">Dosage Forms Considerations</span>
<p style="text-indent:0em;display:inline">Ferrous gluconate is ~12% elemental iron. Specific amount of elemental iron listed for each dosage form is per the manufacturer’s labeling.</p></div>
<div class="block foc drugH1Div" id="F170819"><span class="drugH1">Dosage Forms: US</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Tablet, Oral: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 240 mg [elemental iron 27 mg], 324 mg [elemental iron 38 mg]</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Tablet, Oral [preservative free]: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Ferate: 240 mg [elemental iron 27 mg] [corn free, dairy free, egg free, fragrance free, gluten free, no artificial flavor(s), sodium free, soy free, starch free, sugar free, wheat free, yeast free; contains fd&amp;c blue #1 (brill blue) aluminum lake, fd&amp;c yellow #6(sunset yellow)alumin lake]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 324 mg [elemental iron 37.5 mg]</p></div>
<div class="block geq drugH1Div" id="F170804"><span class="drugH1">Generic Equivalent Available: US</span>
<p style="text-indent:0em;display:inline">Yes</p></div>
<div class="block fee drugH1Div" id="F16323150"><span class="drugH1">Pricing: US</span>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Tablets</b> (Ferate Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">240 (27 Fe) mg (per each): $0.02</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Tablets</b> (Ferrous Gluconate Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">240 (27 Fe) mg (per each): $0.02</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">324 (37.5 Fe) mg (per each): $0.06</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">324 (38 Fe) mg (per each): $0.06 - $0.11</p>
<p style="text-indent:0em;">
<b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>
<div class="block adip drugH1Div" id="F53566693"><span class="drugH1">Additional Information</span>
<p style="text-indent:0em;display:inline">When treating iron deficiency anemias, treat for 3 to 4 months after hemoglobin/hematocrit return to normal in order to replenish total body stores.</p>
<table border="1" data-table-id="fergluc2" frame="border" rules="all">
<caption>
<b>Elemental Iron Content of Iron Salts</b></caption>
<colgroup><col/>
<col align="center"/>
<col align="center"/>
</colgroup><thead valign="middle">
<tr>
<th align="center">
<p style="text-indent:0em;">Iron Salt</p></th>
<th align="center">
<p style="text-indent:0em;">Elemental Iron Content</p>
<p style="text-indent:0em;">(% of salt form)</p></th>
<th align="center">
<p style="text-indent:0em;">Approximate</p>
<p style="text-indent:0em;">Equivalent Doses</p>
<p style="text-indent:0em;">(mg of iron salt)</p></th></tr></thead>
<tbody valign="middle">
<tr>
<td>
<p style="text-indent:0em;">Ferrous fumarate</p></td>
<td align="center">
<p style="text-indent:0em;">33</p></td>
<td align="center">
<p style="text-indent:0em;">197</p></td></tr>
<tr>
<td>
<p style="text-indent:0em;">Ferrous gluconate</p></td>
<td align="center">
<p style="text-indent:0em;">11.6</p></td>
<td align="center">
<p style="text-indent:0em;">560</p></td></tr>
<tr>
<td>
<p style="text-indent:0em;">Ferrous sulfate</p></td>
<td align="center">
<p style="text-indent:0em;">20</p></td>
<td align="center">
<p style="text-indent:0em;">324</p></td></tr>
<tr>
<td>
<p style="text-indent:0em;">Ferrous sulfate, exsiccated</p></td>
<td align="center">
<p style="text-indent:0em;">30</p></td>
<td align="center">
<p style="text-indent:0em;">217</p></td></tr></tbody></table></div>
<div class="block admp drugH1Div" id="F52612835"><span class="drugH1">Administration: Pediatric</span>
<p style="text-indent:0em;display:inline">Oral: Administer with water or juice prior to breakfast and/or between meals for maximum absorption (Kliegman 2020; Oski 1993); may administer with food if GI upset occurs; do not administer with milk or milk products.</p></div>
<div class="block adm drugH1Div" id="F170822"><span class="drugH1">Administration: Adult</span>
<p style="text-indent:0em;display:inline">
<b>Oral:</b> Administer with water or juice prior to breakfast and/or between meals for maximum absorption (Kliegman 2020; Oski 1993); may administer with food if GI upset occurs;. Do not crush or chew tablets.</p></div>
<div class="block sts drugH1Div" id="F2985005"><span class="drugH1">Storage/Stability</span>
<p style="text-indent:0em;display:inline">Store at 20°C to 25°C (68°F to 77°F). Iron is a leading cause of fatal poisoning in children. Store out of children's reach and in child-resistant containers.</p></div>
<div class="block usep drugH1Div" id="F53566892"><span class="drugH1">Use</span>
<p style="text-indent:0em;display:inline">Prevention and treatment of iron deficiency anemias (OTC: FDA approved in adults).</p></div>
<div class="block cyt drugH1Div" id="F13299323"><span class="drugH1">Metabolism/Transport Effects</span>
<p style="text-indent:0em;display:inline">None known.</p></div>
<div class="block dri drugH1Div" id="F170813"><span class="drugH1">Drug Interactions</span><br/><br/><div class="clear"></div><p xmlns=""></p><div class="inner" xmlns=""><p style="text-indent:0em;display:inline"><b>Note</b>: Interacting drugs may <b>not be individually listed below</b> if they are part of a group interaction (eg, individual drugs within “CYP3A4 Inducers [Strong]” are NOT listed).  For a complete list of drug interactions by individual drug name and detailed management recommendations, use the Lexicomp drug interactions program by clicking on the “Launch drug interactions program” link above.</p><p xmlns=""></p></div>
<p style="text-indent:-2em;margin-left:2em;">Alpha-Lipoic Acid: Iron Preparations may decrease the absorption of Alpha-Lipoic Acid. Alpha-Lipoic Acid may decrease the absorption of Iron Preparations.  Management: Separate administration of alpha-lipoic acid from that of any iron-containing compounds by several hours. If alpha-lipoic acid is given 30 minutes before breakfast, then administer oral iron-containing products at lunch or dinner.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Antacids: May decrease the absorption of Iron Preparations. Management: No action is likely necessary for the majority of patients who only use antacids intermittently or occasionally. Consider separating doses of oral iron and antacids in patients who require chronic use of both agents and monitor for reduced iron efficacy.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Baloxavir Marboxil: Polyvalent Cation Containing Products may decrease the serum concentration of Baloxavir Marboxil. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Bictegravir: Iron Preparations may decrease the serum concentration of Bictegravir.  Management: Bictegravir, emtricitabine, and tenofovir alafenamide can be administered with iron preparations under fed conditions, but coadministration with or 2 hours after an iron preparation is not recommended under fasting conditions.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Bisphosphonate Derivatives: Polyvalent Cation Containing Products may decrease the serum concentration of Bisphosphonate Derivatives.  Management: Avoid administration of oral medications containing polyvalent cations within: 2 hours before or after tiludronate/clodronate/etidronate; 60 minutes after oral ibandronate; or 30 minutes after alendronate/risedronate.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Cabotegravir: Polyvalent Cation Containing Products may decrease the serum concentration of Cabotegravir.  Management: Administer polyvalent cation containing products at least 2 hours before or 4 hours after oral cabotegravir.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Cefdinir: Iron Preparations may decrease the serum concentration of Cefdinir. Red-appearing, non-bloody stools may also develop due to the formation of an insoluble iron-cefdinir complex.  Management: Avoid concurrent cefdinir and oral iron when possible. Separate doses by at least 2 hours if combined. Iron-containing infant formulas do not appear alter cefdinir pharmacokinetics, but red-appearing, non-bloody stools may develop when combined.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Deferiprone: Polyvalent Cation Containing Products may decrease the serum concentration of Deferiprone.  Management: Separate administration of deferiprone and oral medications or supplements that contain polyvalent cations by at least 4 hours.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Dimercaprol: May enhance the nephrotoxic effect of Iron Preparations.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Dolutegravir: Iron Preparations may decrease the serum concentration of Dolutegravir.  Management: Administer dolutegravir at least 2 hours before or 6 hours after oral iron. Administer dolutegravir/rilpivirine at least 4 hours before or 6 hours after oral iron. Alternatively, dolutegravir and oral iron can be taken together with food.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Eltrombopag: Polyvalent Cation Containing Products may decrease the serum concentration of Eltrombopag.  Management: Administer eltrombopag at least 2 hours before or 4 hours after oral administration of any polyvalent cation containing product.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Elvitegravir: Polyvalent Cation Containing Products may decrease the serum concentration of Elvitegravir.  Management: Administer elvitegravir 2 hours before or 6 hours after the administration of polyvalent cation containing products.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Entacapone: Iron Preparations may decrease the serum concentration of Entacapone.  Management: Consider separating doses of the agents by 2 or more hours to minimize the effects of this interaction. Monitor for decreased therapeutic effects of levodopa during concomitant therapy, particularly if doses cannot be separated.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ferric Hydroxide Polymaltose Complex: May decrease the serum concentration of Iron Preparations. Specifically, the absorption of oral iron salts may be reduced. Management: Do not administer intravenous (IV) ferric hydroxide polymaltose complex with other oral iron preparations. Therapy with oral iron preparations should begin 1 week after the last dose of IV ferric hydroxide polymaltose complex.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Levodopa: Iron Preparations may decrease the serum concentration of Levodopa. Only applies to oral iron preparations.  Management: Consider separating doses of the agents by 2 or more hours to minimize the effects of this interaction. Monitor for decreased therapeutic effects of levodopa during concomitant therapy, particularly if doses cannot be separated.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Levonadifloxacin: Iron Preparations may decrease the serum concentration of Levonadifloxacin. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Levothyroxine: Iron Preparations may decrease the serum concentration of Levothyroxine.  Management: Separate oral administration of iron preparations and levothyroxine by at least 4 hours.  Separation of doses is not required with parenterally administered iron preparations or levothyroxine.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Methyldopa: Iron Preparations may decrease the serum concentration of Methyldopa.  Management: Consider separating doses of methyldopa and orally administered iron preparation by 2 or more hours. Monitor for decreased efficacy of methyldopa if an oral iron preparation is initiated/dose increase, or increased efficacy if discontinued/dose decreased.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">PenicillAMINE: Polyvalent Cation Containing Products may decrease the serum concentration of PenicillAMINE.  Management: Separate the administration of penicillamine and oral polyvalent cation containing products by at least 1 hour.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Phosphate Supplements: Iron Preparations may decrease the absorption of Phosphate Supplements.  Management: Administer oral phosphate supplements as far apart from the administration of an oral iron preparation as possible to minimize the significance of this interaction.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Polyethylene Glycol-Electrolyte Solution: May decrease the absorption of Iron Preparations. Management: Give oral iron products at least 2 hours before or at least 6 hours after polyethylene glycol-electrolyte solutions that contain magnesium sulfate (Suflave brand). Other products without magnesium do not require dose separation.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Quinolones: Iron Preparations may decrease the serum concentration of Quinolones.  Management: Give oral quinolones at least several hours before (4 h for moxi- and sparfloxacin, 2 h for others) or after (8 h for moxi-, 6 h for cipro/dela-, 4 h for lome-, 3 h for gemi-, and 2 h for enox-, levo-, nor-, oflox-, peflox, or nalidixic acid) oral iron.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Raltegravir: Polyvalent Cation Containing Products may decrease the serum concentration of Raltegravir.  Management: Administer raltegravir 2 hours before or 6 hours after administration of the polyvalent cations. Dose separation may not adequately minimize the significance of this interaction.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Roxadustat: Polyvalent Cation Containing Products may decrease the serum concentration of Roxadustat.  Management: Administer roxadustat at least 1 hour after the administration of oral polyvalent cation containing products.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Tetracyclines: May decrease the absorption of Iron Preparations. Iron Preparations may decrease the serum concentration of Tetracyclines. Management: Avoid this combination if possible. Administer oral iron preparations at least 2 hours before, or 4 hours after, the dose of the oral tetracycline derivative. Monitor for decreased therapeutic effect of oral tetracycline derivatives.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Trientine: Polyvalent Cation Containing Products may decrease the serum concentration of Trientine.  Management: Avoid concomitant use of trientine and polyvalent cations. If oral iron supplements are required, separate the administration by 2 hours. For other oral polyvalent cations, give trientine 1 hour before, or 1 to 2 hours after the polyvalent cation.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Unithiol: May diminish the therapeutic effect of Polyvalent Cation Containing Products.<i> Risk X: Avoid combination</i></p></div>
<div class="block foi drugH1Div" id="F170831"><span class="drugH1">Food Interactions</span>
<p style="text-indent:0em;display:inline">Cereals, dietary fiber, tea, coffee, eggs, and milk may decrease absorption.</p></div>
<div class="block dic drugH1Div" id="F170827"><span class="drugH1">Dietary Considerations</span>
<p style="text-indent:0em;display:inline">May be administered with food to prevent irritation; however, not with cereals, dietary fiber, tea, coffee, eggs, or milk.</p>
<p style="text-indent:-2em;margin-left:2em;">Elemental iron content of ferrous gluconate: 12%.</p>
<p style="text-indent:-2em;margin-left:2em;">Dietary sources of iron include beans, cereal (enriched), clams, beef, lentils, liver, oysters, shrimp, and turkey. Foods that enhance dietary absorption of iron include broccoli, grapefruit, orange juice, peppers and strawberries. Foods that decrease dietary absorption of iron include coffee, dairy products, soy products, spinach, and tea.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dietary reference intake (IOM 2001): </b></p>
<p style="text-indent:-2em;margin-left:4em;">0 to 6 months: Adequate intake: 0.27 mg<b> elemental </b>iron/day.</p>
<p style="text-indent:-2em;margin-left:4em;">7 to 12 months: RDA: 11 mg<b> elemental </b>iron/day.</p>
<p style="text-indent:-2em;margin-left:4em;">1 to 3 years: RDA: 7 mg<b> elemental </b>iron/day.</p>
<p style="text-indent:-2em;margin-left:4em;">4 to 8 years: RDA: 10 mg<b> elemental </b>iron/day.</p>
<p style="text-indent:-2em;margin-left:4em;">9 to 13 years: RDA: 8 mg<b> elemental </b>iron/day.</p>
<p style="text-indent:-2em;margin-left:4em;">14 to 18 years: RDA:</p>
<p style="text-indent:-2em;margin-left:6em;">Males: 11 mg<b> elemental </b>iron/day.</p>
<p style="text-indent:-2em;margin-left:6em;">Females: 15 mg<b> elemental </b>iron/day.</p>
<p style="text-indent:-2em;margin-left:6em;">Pregnant patients: 27 mg<b> elemental </b>iron/day.</p>
<p style="text-indent:-2em;margin-left:6em;">Lactating patients: 10 mg<b> elemental </b>iron/day.</p>
<p style="text-indent:-2em;margin-left:4em;">19 to 50 years: RDA:</p>
<p style="text-indent:-2em;margin-left:6em;">Males: 8 mg<b> elemental </b>iron/day.</p>
<p style="text-indent:-2em;margin-left:6em;">Females: 18 mg<b> elemental </b>iron/day.</p>
<p style="text-indent:-2em;margin-left:6em;">Pregnant patients: 27 mg<b> elemental </b>iron/day.</p>
<p style="text-indent:-2em;margin-left:6em;">Lactating patients: 9 mg<b> elemental </b>iron/day.</p>
<p style="text-indent:-2em;margin-left:4em;">≥50 years: RDA: 8 mg<b> elemental </b>iron/day.</p></div>
<div class="block pri drugH1Div" id="F6789289"><span class="drugH1">Pregnancy Considerations</span>
<p style="text-indent:0em;">Iron transfer to the fetus is regulated by the placenta (BSH [Pavord 2020]; NAS 2020).</p>
<p style="text-indent:0em;margin-top:2em;">Maternal iron requirements increase during pregnancy. Untreated iron deficiency and iron deficiency anemia (IDA) in pregnant patients are associated with adverse pregnancy outcomes, including low birth weight, preterm birth, and increased perinatal mortality (ACOG 2021; BSH [Pavord 2020]). Maternal iron deficiency is also associated with fatigue, increased risk of postpartum depression, and possibly postpartum hemorrhage (BSH [Pavord 2020]).</p>
<p style="text-indent:0em;margin-top:2em;">Oral and parenteral iron are effective at replacing iron stores in pregnant patients (ACOG 2021). Most studies note iron therapy improves maternal hematologic parameters; however, data related to clinical outcomes in the mother and neonate are limited (FIGO 2019; NAS 2020; USPSTF [Siu 2015]). Use of low-dose supplemental iron is recommended for all pregnant patients beginning in the first trimester or first prenatal visit to prevent anemia at term (ACOG 2021).</p>
<p style="text-indent:0em;margin-top:2em;">Ferrous gluconate has been evaluated for the treatment of IDA during pregnancy (Peña-Rosas 2015; Reveiz 2011; Rogozińska 2021). Ferrous salts are preferred over ferric salts for the oral management of IDA in pregnancy due to better absorption and bioavailability (BSH [Pavord 2020]). Iron supplementation is recommended for 3 months once hemoglobin is within the normal range and at least 6 weeks postpartum to replenish maternal iron stores (BSH [Pavord 2020]; FIGO 2019). Iron supplementation is recommended in addition to use of prenatal vitamins in pregnant patients diagnosed with IDA (ACOG 2021). Enteric-coated and slow/sustained-release preparations may be less effective due to decreased absorption, and use should be avoided (ACOG 2021; BSH [Pavord 2020]).</p></div>
<div class="block mopp drugH1Div" id="F53566893"><span class="drugH1">Monitoring Parameters</span>
<p style="text-indent:0em;display:inline">Hemoglobin and hematocrit; consider additional tests such as RBC count, RBC indices, serum ferritin, transferrin saturation, total iron-binding capacity, serum iron concentration, and erythrocyte protoporphyrin concentration (CDC 1998).</p></div>
<div class="block rerp drugH1Div" id="F53566483"><span class="drugH1">Reference Range</span>
<p style="text-indent:-2em;margin-left:2em;">Serum iron (AAP [Kleinman 2019]):</p>
<p style="text-indent:-2em;margin-left:4em;">≤6 weeks: 100 to 250 mcg/dL.</p>
<p style="text-indent:-2em;margin-left:4em;">7 weeks to 11 months: 40 to 100 mcg/dL.</p>
<p style="text-indent:-2em;margin-left:4em;">1 to 10 years: 50 to 120 mcg/dL.</p>
<p style="text-indent:-2em;margin-left:4em;">≥11 years:</p>
<p style="text-indent:-2em;margin-left:6em;">Female: 30 to 160 mcg/dL.</p>
<p style="text-indent:-2em;margin-left:6em;">Male: 50 to 170 mcg/dL.</p>
<p style="text-indent:-2em;margin-left:2em;">Total iron binding capacity (AAP [Kleinman 2019]):</p>
<p style="text-indent:-2em;margin-left:4em;">≤2 months: 59 to 175 mcg/dL.</p>
<p style="text-indent:-2em;margin-left:4em;">3 months to 17 years: 250 to 400 mcg/dL.</p>
<p style="text-indent:-2em;margin-left:4em;">≥18 years: 240 to 450 mcg/dL.</p></div>
<div class="block pha drugH1Div" id="F170807"><span class="drugH1">Mechanism of Action</span>
<p style="text-indent:0em;display:inline">Replaces iron found in hemoglobin, myoglobin, and enzymes; allows the transportation of oxygen via hemoglobin</p></div>
<div class="block phk drugH1Div" id="F170824"><span class="drugH1">Pharmacokinetics (Adult Data Unless Noted)</span>
<p style="text-indent:0em;display:inline">Onset of action: Hematologic response: Oral: 3 to 10 days; peak reticulocytosis occurs in 5 to 10 days, and hemoglobin values increase in ∼2 to 4 weeks</p></div>
<div class="list fbnlist drugH1Div drugBrandNames" id="F170828"><span class="drugH1">Brand Names: International</span><div class="ibn-search drugBrandNames"></div>
<div class="collapsible-indication brand-names-accordion drugBrandNames"><span class="collapsible-indication-title">International Brand Names by Country</span><div class="collapsible-indication-wrap-frame drugBrandNames"><div class="collapsible-indication-wrap drugBrandNames">For country code abbreviations (<a class="graphic graphic_table" href="/d/html/116421.html" rel="external">show table</a>)<br xmlns=""/><br/><ul>
<li>
<span class="countryCode">(AE)</span> <span class="country">United Arab Emirates</span><span class="countrySeparator">: </span><span class="drugName">Fergon | Glucofer</span>;</li>
<li>
<span class="countryCode">(DE)</span> <span class="country">Germany</span><span class="countrySeparator">: </span><span class="drugName">Ferrum</span>;</li>
<li>
<span class="countryCode">(EG)</span> <span class="country">Egypt</span><span class="countrySeparator">: </span><span class="drugName">Glucofer</span>;</li>
<li>
<span class="countryCode">(IT)</span> <span class="country">Italy</span><span class="countrySeparator">: </span><span class="drugName">Ferro Gluc.Eg</span>;</li>
<li>
<span class="countryCode">(JO)</span> <span class="country">Jordan</span><span class="countrySeparator">: </span><span class="drugName">Glucofer</span>;</li>
<li>
<span class="countryCode">(KW)</span> <span class="country">Kuwait</span><span class="countrySeparator">: </span><span class="drugName">Apo-ferrous gluconate | Fergon</span>;</li>
<li>
<span class="countryCode">(LB)</span> <span class="country">Lebanon</span><span class="countrySeparator">: </span><span class="drugName">Apo-ferrous gluconate | Fergon</span>;</li>
<li>
<span class="countryCode">(LT)</span> <span class="country">Lithuania</span><span class="countrySeparator">: </span><span class="drugName">Apo ferrum</span>;</li>
<li>
<span class="countryCode">(MY)</span> <span class="country">Malaysia</span><span class="countrySeparator">: </span><span class="drugName">Apo-ferrous gluconate</span>;</li>
<li>
<span class="countryCode">(RO)</span> <span class="country">Romania</span><span class="countrySeparator">: </span><span class="drugName">Ferronal | Gluconat feros</span>;</li>
<li>
<span class="countryCode">(RU)</span> <span class="country">Russian Federation</span><span class="countrySeparator">: </span><span class="drugName">Ferronal</span>;</li>
<li>
<span class="countryCode">(SA)</span> <span class="country">Saudi Arabia</span><span class="countrySeparator">: </span><span class="drugName">Apo-ferrous gluconate</span>;</li>
<li>
<span class="countryCode">(TH)</span> <span class="country">Thailand</span><span class="countrySeparator">: </span><span class="drugName">Ferrin</span>;</li>
<li>
<span class="countryCode">(UA)</span> <span class="country">Ukraine</span><span class="countrySeparator">: </span><span class="drugName">Ferronal</span></li></ul></div>
</div>
</div>
</div>
</div><div class="headingAnchor" id="references"><ol id="reference">
<li>
<div class="reference">
                  American Academy of Pediatrics Committee on Nutrition. Kleinman RE, Greer FR, eds. <i>Pediatric Nutrition Handbook</i>. 8th ed. Itasca, IL: American Academy of Pediatrics; 2019.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-ABIM.1">
<a name="ABIM.1"></a>American Board of Internal Medicine (ABIM). Laboratory Test Reference Ranges. <i>Lexi-Drugs</i>. UpToDate Lexidrug. Waltham, MA: UpToDate Inc. https://online.lexi.com. Accessed December 11, 2023.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-34293770">
<a name="34293770"></a>American College of Obstetricians and Gynecologists' Committee on Practice Bulletins—Obstetrics. Anemia in pregnancy: ACOG practice bulletin, number 233. <i>Obstet Gynecol</i>. 2021;138(2):e55-e64. doi:10.1097/AOG.0000000000004477<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ferrous-gluconate-pediatric-drug-information/abstract-text/34293770/pubmed" id="34293770" target="_blank">34293770</a>]</span>
</div>
</li>
<li>
<div class="reference">
                  Auerbach M. Treatment of iron deficiency anemia in adults. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed October 13, 2021.</div>
</li>
<li>
<div class="reference">
                  Carney LN, Nepa A, Cohen SS, et al. Parenteral and Enteral Nutrition Support: Determining the Best Way to Feed. In: Corkins MR, Balint J, Bobo E, et al, eds. <i>The A.S.P.E.N Pediatric Nutrition Support Core Curriculum</i>. Silver Spring, MD: American Society of Parenteral and Enteral Nutrition; 2010:440-441.</div>
</li>
<li>
<div class="reference">
                  Corkins MR, Balint J, Bobo E, et al, eds. <i>The A.S.P.E.N Pediatric Nutrition Support Core Curriculum</i>. 2nd ed. Silver Spring, MD: American Society of Parenteral and Enteral Nutrition; 2015.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-10705077">
<a name="10705077"></a>Dorea JG. Iron and copper in human milk. <i>Nutrition</i>. 2000;16(3):209-220. doi:10.1016/s0899-9007(99)00287-7<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ferrous-gluconate-pediatric-drug-information/abstract-text/10705077/pubmed" id="10705077" target="_blank">10705077</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21548016">
<a name="21548016"></a>El-Farrash RA, Ismail EA, Nada AS. Cord blood iron profile and breast milk micronutrients in maternal iron deficiency anemia. <i>Pediatr Blood Cancer</i>. 2012;58(2):233-238. doi:10.1002/pbc.23184<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ferrous-gluconate-pediatric-drug-information/abstract-text/21548016/pubmed" id="21548016" target="_blank">21548016</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-9363415">
<a name="9363415"></a>Emmett PM, Rogers IS. Properties of human milk and their relationship with maternal nutrition. <i>Early Hum Dev</i>. 1997;(49)(suppl):S7-S28. doi:10.1016/s0378-3782(97)00051-0<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ferrous-gluconate-pediatric-drug-information/abstract-text/9363415/pubmed" id="9363415" target="_blank">9363415</a>]</span>
</div>
</li>
<li>
<div class="reference">
                  Ferate Tabs (ferrous gluconate) [prescribing information]. Livonia, MI: Major Pharmaceuticals; April 2016.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30710364">
<a name="30710364"></a>FIGO Working Group on Good Clinical Practice in Maternal-Fetal Medicine. Good clinical practice advice: iron deficiency anemia in pregnancy. <i>Int J Gynaecol Obstet</i>. 2019;144(3):322-324. doi:10.1002/ijgo.12740<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ferrous-gluconate-pediatric-drug-information/abstract-text/30710364/pubmed" id="30710364" target="_blank">30710364</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24479203">
<a name="24479203"></a>
<i>Guideline: Intermittent Iron Supplementation in Preschool and School-Age Children</i>. Geneva: World Health Organization; 2011.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ferrous-gluconate-pediatric-drug-information/abstract-text/24479203/pubmed" id="24479203" target="_blank">24479203</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-34514189">
<a name="34514189"></a>Gutiérrez O. Treatment of iron deficiency anemia in CKD and end-stage kidney disease. <i>Kidney Int Rep. </i>2021;6(9):2261-2269. doi:10.1016/j.ekir.2021.05.020<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ferrous-gluconate-pediatric-drug-information/abstract-text/34514189/pubmed" id="34514189" target="_blank">34514189</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24215034">
<a name="24215034"></a>Hershko C and Camaschella C. How I treat unexplained refractory iron deficiency anemia. <i>Blood.</i> 2014;123(3):326-333. doi:10.1182/blood-2013-10-512624<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ferrous-gluconate-pediatric-drug-information/abstract-text/24215034/pubmed" id="24215034" target="_blank">24215034</a>]</span>
</div>
</li>
<li>
<div class="reference">
                  IOM (Institute of Medicine), <i>Dietary Reference Intakes for Vitamin A, Vitamin K, Arsenic, Boron, Chromium, Copper, Iodine, Iron, Manganese, Molybdenum, Nickel, Silicon, Vanadium, and Zinc</i>, Washington, DC: National Academy Press; 2001.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12387433">
<a name="12387433"></a>Kazal LA Jr. Prevention of iron deficiency in infants and toddlers. <i>Am Fam Physician</i>. 2002;66(7):1217-1224.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ferrous-gluconate-pediatric-drug-information/abstract-text/12387433/pubmed" id="12387433" target="_blank">12387433</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-KDIGO.1">
<a name="KDIGO.1"></a>Kidney Disease: Improving Global Outcomes (KDIGO) CKD Work Group. KDIGO 2012 clinical practice guidelines for anemia in chronic kidney disease (2012). https://kdigo.org/wp-content/uploads/2016/10/KDIGO-2012-Anemia-Guideline-English.pdf. Accessed December 11, 2023.</div>
</li>
<li>
<div class="reference">
                  Kliegman RM and St. Geme J, eds. <i>Nelson Textbook of Pediatrics</i>. 21st ed. Philadelphia, PA: Saunders Elsevier; 2020.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-18310187">
<a name="18310187"></a>Kumar A, Rai AK, Basu S, et al. Cord blood and breast milk iron status in maternal anemia. <i>Pediatrics</i>. 2008;121(3):e673-e677. doi:10.1542/peds.2007-1986<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ferrous-gluconate-pediatric-drug-information/abstract-text/18310187/pubmed" id="18310187" target="_blank">18310187</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22157204">
<a name="22157204"></a>Liu K, Kaffes AJ. Iron deficiency anaemia: a review of diagnosis, investigation and management. <i>Eur J Gastro Hep</i>. 2012;24(2):109-116.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ferrous-gluconate-pediatric-drug-information/abstract-text/22157204/pubmed" id="22157204" target="_blank">22157204</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26289639">
<a name="26289639"></a>Moretti D, Goede JS, Zeder C, et al. Oral iron supplements increase hepcidin and decrease iron absorption from daily or twice-daily doses in iron-depleted young women. <i>Blood</i>. 2015;126(17):1981-1989. doi:10.1182/blood-2015-05-642223<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ferrous-gluconate-pediatric-drug-information/abstract-text/26289639/pubmed" id="26289639" target="_blank">26289639</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-NAS.2020">
<a name="NAS.2020"></a>National Academies of Sciences, Engineering, and Medicine 2020. <i>Nutrition During Pregnancy and Lactation: Exploring New Evidence: Proceedings of a Workshop</i>. The National Academies Press; 2020. https://doi.org/10.17226/25841</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-8515791">
<a name="8515791"></a>Oski FA. Iron deficiency in infancy and childhood. <i>N Engl J Med</i>. 1993;329(3):190-193. doi:10.1056/NEJM199307153290308<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ferrous-gluconate-pediatric-drug-information/abstract-text/8515791/pubmed" id="8515791" target="_blank">8515791</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31578718">
<a name="31578718"></a>Pavord S, Daru J, Prasannan N, Robinson S, Stanworth S, Girling J; BSH Committee. UK guidelines on the management of iron deficiency in pregnancy. <i>Br J Haematol</i>. 2020;188(6):819-830. doi:10.1111/bjh.16221<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ferrous-gluconate-pediatric-drug-information/abstract-text/31578718/pubmed" id="31578718" target="_blank">31578718</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26198451">
<a name="26198451"></a>Peña-Rosas JP, De-Regil LM, Garcia-Casal MN, et al. Daily oral iron supplementation during pregnancy. <i>Cochrane Database Syst Rev</i>. 2015;22;(7):CD004736. doi:10.1002/14651858.CD004736.pub5<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ferrous-gluconate-pediatric-drug-information/abstract-text/26198451/pubmed" id="26198451" target="_blank">26198451</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28609534">
<a name="28609534"></a>Powers JM, Buchanan GR, Adix L, Zhang S, Gao A, McCavit TL. Effect of low-dose ferrous sulfate vs iron polysaccharide complex on hemoglobin concentration in young children with nutritional iron-deficiency anemia: a randomized clinical trial. <i>JAMA</i>. 2017;317(22):2297-2304. doi:10.1001/jama.2017.6846<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ferrous-gluconate-pediatric-drug-information/abstract-text/28609534/pubmed" id="28609534" target="_blank">28609534</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-9563847">
<a name="9563847"></a>Recommendations to Prevent and Control Iron Deficiency in the United States. Centers for Disease Control and Prevention. <i>MMWR Recomm Rep.</i> 1998;47(RR-3):1-29.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ferrous-gluconate-pediatric-drug-information/abstract-text/9563847/pubmed" id="9563847" target="_blank">9563847</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-3969339">
<a name="3969339"></a>Reeves JD, Yip R. Lack of adverse side effects of oral ferrous sulfate therapy in 1-year-old infants. <i>Pediatrics</i>. 1985;75(2):352-355.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ferrous-gluconate-pediatric-drug-information/abstract-text/3969339/pubmed" id="3969339" target="_blank">3969339</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21975735">
<a name="21975735"></a>Reveiz L, Gyte GM, Cuervo LG, et al. Treatments for iron-deficiency anaemia in pregnancy. <i>Cochrane Database Syst Rev</i>. 2011;(10):CD003094. doi:10.1002/14651858.CD003094.pub3<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ferrous-gluconate-pediatric-drug-information/abstract-text/21975735/pubmed" id="21975735" target="_blank">21975735</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16194646">
<a name="16194646"></a>Rimon E, Kagansky N, Kagansky M, et al. Are We Giving Too Much Iron? Low-Dose Iron Therapy is Effective in Octogenarians. <i>Am J Med. </i>2005;118(10):1142-1147.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ferrous-gluconate-pediatric-drug-information/abstract-text/16194646/pubmed" id="16194646" target="_blank">16194646</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-34171281">
<a name="34171281"></a>Rogozińska E, Daru J, Nicolaides M, et al. Iron preparations for women of reproductive age with iron deficiency anaemia in pregnancy (FRIDA): a systematic review and network meta-analysis. <i>Lancet Haematol</i>. 2021;8(7):e503-e512. doi:10.1016/S2352-3026(21)00137-X<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ferrous-gluconate-pediatric-drug-information/abstract-text/34171281/pubmed" id="34171281" target="_blank">34171281</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26344176">
<a name="26344176"></a>Siu AL; US Preventive Services Task Force. Screening for iron deficiency anemia and iron supplementation in pregnant women to improve maternal health and birth outcomes: US Preventive Services Task Force Recommendation Statement. <i>Ann Intern Med</i>. 2015;163(7):529-36. doi:10.7326/M15-1707<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ferrous-gluconate-pediatric-drug-information/abstract-text/26344176/pubmed" id="26344176" target="_blank">26344176</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29032957">
<a name="29032957"></a>Stoffel NU, Cercamondi CI, Brittenham G, et al. Iron absorption from oral iron supplements given on consecutive versus alternate days and as single morning doses versus twice-daily split dosing in iron-depleted women: two open-label, randomised controlled trials. <i>Lancet Haematol</i>. 2017;4(11):e524-e533. doi:10.1016/S2352-3026(17)30182-5<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ferrous-gluconate-pediatric-drug-information/abstract-text/29032957/pubmed" id="29032957" target="_blank">29032957</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31413088">
<a name="31413088"></a>Stoffel NU, Zeder C, Brittenham GM, Moretti D, Zimmermann MB. Iron absorption from supplements is greater with alternate day than with consecutive day dosing in iron-deficient anemic women. <i>Haematologica</i>. 2020;105(5):1232-1239. doi:10.3324/haematol.2019.220830<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ferrous-gluconate-pediatric-drug-information/abstract-text/31413088/pubmed" id="31413088" target="_blank">31413088</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27195351">
<a name="27195351"></a>World Health Organization (WHO): Guideline:<i> Daily Iron Supplementation in Adult Women and Adolescent Girls</i>. World Health Organization; 2016a. <a href="https://www.ncbi.nlm.nih.gov/books/NBK361888/" target="_blank">https://www.ncbi.nlm.nih.gov/books/NBK361888/</a>.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ferrous-gluconate-pediatric-drug-information/abstract-text/27195351/pubmed" id="27195351" target="_blank">27195351</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27195348">
<a name="27195348"></a>World Health Organization (WHO): Guideline:<i> Daily Iron Supplementation in Infants and Children</i>. World Health Organization; 2016b. <a href="https://www.ncbi.nlm.nih.gov/books/NBK362032/" target="_blank">https://www.ncbi.nlm.nih.gov/books/NBK362032/</a>.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ferrous-gluconate-pediatric-drug-information/abstract-text/27195348/pubmed" id="27195348" target="_blank">27195348</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27583315">
<a name="27583315"></a>World Health Organization (WHO). <i>Guideline: Iron Supplementation in Postpartum Women</i>. World Health Organization; 2016c.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ferrous-gluconate-pediatric-drug-information/abstract-text/27583315/pubmed" id="27583315" target="_blank">27583315</a>]</span>
</div>
</li>
<li>
<div class="reference">
                  World Health Organization (WHO). Breastfeeding and maternal medication, recommendations for drugs in the eleventh WHO model list of essential drugs. https://apps.who.int/iris/handle/10665/62435. Published 2002.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-WHO.1">
<a name="WHO.1"></a>World Health Organization (WHO). Haemoglobin concentrations for the diagnosis of anaemia and assessment of severity. Vitamin and Mineral Nutrition Information System. https://iris.who.int/bitstream/handle/10665/85839/WHO_NMH_NHD_MNM_11.1_eng.pdf?sequence=22. Published 2011. Accessed December 11, 2023.x</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-WHO.2">
<a name="WHO.2"></a>World Health Organization (WHO). Serum ferritin concentrations for the assessment of iron status in individuals and populations: technical brief. https://iris.who.int/bitstream/handle/10665/337666/9789240008526-eng.pdf?sequence=1. Published 2020. Accessed December 11, 2023.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-11533326">
<a name="11533326"></a>Zlotkin S, Arthur P, Antwi KY, Yeung G. Randomized, controlled trial of single versus 3-times-daily ferrous sulfate drops for treatment of anemia. <i>Pediatrics</i>. 2001;108(3):613-616. doi:10.1542/peds.108.3.613<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ferrous-gluconate-pediatric-drug-information/abstract-text/11533326/pubmed" id="11533326" target="_blank">11533326</a>]</span>
</div>
</li></ol></div><div id="topicVersionRevision">Topic 13055 Version 239.0</div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
